1Wolf P A,Abbott R D,Kannel W B. Atrial fibrillation as an independent risk factor for stroke:the Framingham Study[J].Stroke,1991,(08):983-988.
2Fang M C,Go A S,Chang Y. Warfarin discontinuation after starting warfarin for atrial fibrillation[J].Circ Cardiovasc Qual Outcomes,2010,(06):624-631.
3Poller L,Jespersen J,Ibrahim S. Dabigatran versus warfarin in pat ients withatrialfibrillation[J].New England Journal of Medicine,2009,(27):2673-426745.
4Perzborn E,Strassburger J,Wilmen A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral,direct Factor Xa inhibitor[J].Journal of Thrombosis and Haemostasis,2005,(03):514-521.
5Mueck W,Becka M,Kubitza D. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral,direct factor xa inhibitor-in healthy subjects[J].International Journal of Clinical Pharmacology and Therapeutics,2007,(06):335-344.
6Patel M R,Mahaffey K W,Garg J. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].New England Journal of Medicine,2011,(10):883-891.
7Eikelboom J W,Weitz J I. New anticoagulants[J].Circulation,2010,(13):1523-1532.
8Granger C B,Alexander J H,Mcmurray J J. Apixaban versus warfarin in patients with atrial fibrillation[J].New England Journal of Medicine,2011,(11):981-992.
同被引文献42
1武忠弼.病理学[M].北京：人民卫生出版社,1996.90.
2Spencer F A, Emery C, Lessard D,et al. The Worcester venous tbrombo- embolism study:a population - based study of the clinical epidemiology of venous thromboembolism[ J]. J Gen Intern Med ,2006,21 (7) :792 - 727.
3Pinto D J, Smahheer J M, Cheney D L,et al. FactorXa lnhibitors:next - Generation Antithrombotic Agents [ J ]. J Med Chem, 2010,53 ( 17 ) : 6243 - 6274.
4Alemida L, Falcao A, Vazda Silva M, et al. Effect of nebicapone on the pharmacokineties and pharmacodynamics of warfarin in healthy subljects [ J]. Eur J Clin Pharmacol,2008,64(10) :961.
5A1 Sallami H,Ferguson R, Wilkins G,et al. Bleeding events in patients receiving enoxaparin for the management of non - ST - e|evation acute coronary syndrome at Dunedin Public Hospital[ J]. New Zealand medical journal ,2008,121 ( 1285 ) :87.
7Vchiyama S, Ibayasli S, Matsumoto M,et al. Dabigatran and faetorXa in- hibitor for stroke prevention in patients with nonvalvular atrial fibrillation [ J]. J Strike Cerebrovase Dis,2012,21 : 165 - 173.
8Johansson S,Cullberg M, Eriksson U G,et al. single dose pharmacolei- nerves, phatmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects[ J]. Int J Clin Phar- macol Ther,2012,49 : 258 - 267.
9Mega J L,Braunwald E,Wiviott S D,et al. Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med,2012,366( 1 ) :9 - 19.
10Connolly SJ,Wallentin L,Ezekowitz MD,et al.The long-term multicenter observational study of Dabigatran Treatment in Patients With Atrial Fibrillation(RELY-ABLE)Study[J].Circulation,2013,128(3):237-243.
